Screener
Ultragenyx Pharmaceutical RARE Liabilities For Sales Of Future Royalties Current
Liabilities For Sales Of Future Royalties Current at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:LiabilitiesForSalesOfFutureRoyaltiesCurrent.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $39 | $31 |
| Accrued liabilities | 221 | 265 |
| Liabilities for sales of future royalties | 76 | 69 |
| Other liabilities | 15 | 19 |
| Total current liabilities | 351 | 384 |
| Deferred tax liabilities | 30 | 30 |
| Liabilities for sales of future royalties | 1,126 | 1,147 |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's liabilities for sales of future royalties current?
- Ultragenyx Pharmaceutical (RARE) reported liabilities for sales of future royalties current of $76M in Q2 2026.
- How has Ultragenyx Pharmaceutical's liabilities for sales of future royalties current changed year-over-year?
- Ultragenyx Pharmaceutical's liabilities for sales of future royalties current increased by 19.0% year-over-year, from $63.86M to $76M.
- What does liabilities for sales of future royalties current mean?
- Liabilities For Sales Of Future Royalties Current as reported by Ultragenyx Pharmaceutical Inc..
Ask your AI about Ultragenyx Pharmaceutical's liabilities for sales of future royalties current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude